Last updated: June 27, 2026
Eagle Pharmaceuticals, Inc. v. Apotex Inc. (No. 1:24-cv-00064) is a federal patent case filed in 2024 against Apotex tied to FDA small-molecule drug approval activity. The action is a standard US Hatch-Waxman infringement posture: the plaintiff asserts one or more Orange-Book-listed patents, and the defendant typically responds with non-infringement, invalidity, and/or statutory defenses tied to the ANDA paragraph certification (often Paragraph IV for early entry).
No docket facts can be stated here because the case caption and docket number are insufficient to extract the asserted patents, Orange Book drugs, filing dates, claim construction positions, injunction or settlement status, and any rulings.
Because the question requires a litigation summary and analysis, providing anything beyond the caption would risk fabricating key case-specific facts (asserted patents, parties, venue, procedural posture, and outcomes).
What patents are asserted in Eagle Pharmaceuticals v. Apotex 1:24-cv-00064?
Answer (required for litigation analysis): This cannot be determined from the provided identifier alone.
What Orange Book patents does Eagle list for the asserted product?
No reliable determination is possible without the specific FDA NDA/ANDA product and the patent numbers and expiration dates that appear in the Orange Book for that product.
Which ANDA or certification paragraph triggered the suit?
No reliable determination is possible without the complaint’s Hatch-Waxman section identifying the ANDA number and the paragraph certification (I, II, III, or IV).
Where is the case filed and what is the court docket history?
No reliable determination is possible without access to the docket entries (complaint filing date, amended complaint, answer, motions, and any rulings).
What is the procedural posture of Eagle v. Apotex 1:24-cv-00064 (motions, rulings, trial dates)?
Answer: This cannot be determined from the case number provided alone.
Has the court issued claim construction or summary judgment?
No reliable determination is possible without docket orders.
Is there a preliminary injunction request or stay pending litigation?
No reliable determination is possible without docket entries and any briefing orders.
What is the current status: active, stayed, dismissed, or settled?
No reliable determination is possible without settlement or dismissal docket facts.
What claims and legal theories does Eagle likely assert in 1:24-cv-00064?
Answer: This cannot be stated with specificity without the complaint.
Infringement theory (manufacture, use, sale, offer to sell, importation)
The asserted infringement basis is complaint-specific and depends on the Orange-Book-listed patents and the proposed ANDA product description.
Invalidity defenses Apotex typically raises
Invalidity theories (35 USC §§ 102, 103, and 112) and non-infringement are common, but the particular defenses depend on the patents-in-suit and claim elements.
Statutory defenses (e.g., noninfringement under FDA carve-outs)
Whether any carve-out or statutory defense is raised depends on the ANDA paragraph and the claim language tied to regulatory approval.
How do Paragraph IV ANDA challenges relate to Eagle v. Apotex 1:24-cv-00064?
Answer: The ANDA paragraph certification and the 30-month stay or its termination are not determinable without the FDA filing details stated in the complaint.
Is there a 30-month stay and what is its expiration?
This is contingent on the specific ANDA and the litigation timeline.
Did Apotex lose exclusivity early due to settlement or court timing?
This depends on whether the parties reached settlement, the court’s rulings timing, and whether the ANDA approval was permitted.
What is the patent-by-patent risk profile for Apotex’s launch?
This requires the patent list, expiration dates, and any court findings.
What is the infringement/invalidity analysis for the specific patents asserted?
Answer: Cannot be produced without the patent numbers and claim text.
Method-of-use versus composition-of-matter versus formulation patents
Whether the asserted patents are formulation, process, method-of-use, or composition-of-matter drives the infringement analysis. No classification is possible without the asserted patents.
Claim construction impact
Claim construction governs whether Apotex’s proposed product falls within the claim scope. Court construction requires docket orders.
Prior art landscape
A prior art invalidity analysis requires the specific claims and priority dates and the references Apotex relies upon in its invalidity contentions.
Has there been settlement or dismissal in Eagle v. Apotex 1:24-cv-00064?
Answer: Cannot be determined from the case number alone.
If settled, what typical structure would apply?
Settlement in ANDA patent cases can include:
- no-entry agreements through a stated date,
- carve-outs for specific dosages or manufacturing changes,
- covenant-not-to-sue for design-arounds,
- payment terms or side letters, and
- mutual timing obligations tied to FDA approval.
But identifying the specific terms requires settlement filings or docket entries.
If dismissed, was it with prejudice and why?
Dismissal reason is docket-specific and includes jurisdictional, procedural, or merits-based grounds.
Orange Book status: what is protected and when does exclusivity end for the Eagle product?
Answer: Cannot be determined without identifying the NDA/ANDA drug and the Orange-Book-listed patents at issue.
Patent expiration versus regulatory exclusivity
Orange-Book patents can expire before or after FDA exclusivity triggers. Exact timelines require the listed patents’ expiration dates and any pediatric exclusivity, patent term adjustments, or exclusivity periods.
How many patents cover the product and what are their expiration dates?
This cannot be counted without the Orange Book listing tied to the case.
Does generic entry depend on each patent or a subset?
This depends on which patents are asserted and which are invalidated or found not infringed.
How does Apotex’s ANDA risk compare to other generic entrants for the same Eagle product?
Answer: Cannot be determined without:
- the drug identity,
- Apotex’s ANDA number and status,
- co-pending paragraph IV challengers, and
- any litigation coordination among generics.
Which other companies filed Paragraph IV certifications?
This requires the Orange Book and FDA ANDA certification history.
Do design-arounds avoid infringement of the asserted formulation/process claims?
Requires claim language and Apotex’s proposed product description.
Commercial and R&D exposure: what is at stake for Eagle and Apotex?
Answer: Cannot be quantified without the product, exclusivity timeline, and any court timelines affecting FDA approval.
If Apotex launches “at risk,” what price or market share pressure could occur?
This depends on the product’s revenue and competitive class, none of which can be tied to this case without the drug identity.
If Eagle secures injunction or wins early, how does it impact Apotex’s timeline?
Depends on rulings and any preliminary injunction posture.
If there is a stay, when can Apotex realistically enter?
Requires the ANDA and litigation chronology.
Key Takeaways
- The docket identifier (1:24-cv-00064) and caption alone do not provide the case-specific details needed for a litigation summary: asserted patents, ANDA and paragraph certification, procedural history, rulings, and any settlement or dismissal terms.
- A credible litigation analysis requires the complaint’s asserted patent list and the docket’s motion and order entries; those are not present in the provided inputs.
FAQs
- What is the venue and judge assignment for Eagle Pharmaceuticals v. Apotex (1:24-cv-00064)?
- Which ANDA number and paragraph certification does Apotex use in Eagle v. Apotex (1:24-cv-00064)?
- What patents are listed on the complaint for Eagle’s infringement claims in 1:24-cv-00064?
- Has the court issued any claim construction or summary judgment orders in Eagle v. Apotex (1:24-cv-00064)?
- Did Eagle and Apotex reach a settlement, and what entry date or covenant terms were filed in the docket?
References (APA)
- Federal Trade Commission Act.
- None (no sources cited).
